LPM682000012

LPM682000012 is an investigational small molecule antidepressant being developed by Luye Pharma (Shandong Luye Pharmaceutical Co., Ltd.) for the treatment of depressive disorder. It is currently in Phase 1 clinical development in China, with studies such as CTR20252765 evaluating its safety, tolerability, pharmacokinetics, and the effect of food on its absorption in healthy adult subjects. As a novel therapeutic candidate within Luye Pharma's central nervous system (CNS) pipeline, LPM682000012 is administered orally in tablet form. While its specific molecular mechanism of action has not been publicly disclosed in early clinical stages, it represents a new chemical entity aimed at addressing the unmet needs of patients with major depressive disorder.